Copilot Sent by Copilot: Enzolytics ITV-1 is a patented immunotherapy cancer treatment developed by Enzolytics, Inc. It’s also known as Immune Therapeutic Vaccine-1 (ITV-1). Here are some key points about it:
Composition: ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), which is the active drug substance. IPF is a purified extract of porcine pepsin. Effectiveness: Studies have shown that ITV-1 is effective in treating HIV/AIDS by modulating the immune system12. It has broad efficacy with low toxicity. Cancer Immunotherapy: Enzolytics has entered into a worldwide exclusive licensing agreement for US Patent #8067531-B2, which applies immunotherapy treatment to the global fight against cancer. The company is exploring therapeutic applications of this patent and preparing for FDA in-vitro studies. ITV-1 does not substitute for existing chemotherapy treatments3. Clinical Trials: Progress is being made to move forward with clinical trials in Europe to assess the effects of ITV-1 on diabetic patients. Additionally, efforts continue for permitting ITV-1 for HIV/AIDS treatment with the European Medicine Association (EMA)34. Manufacturing Facility: Enzolytics is negotiating the acquisition of a pharmaceutical manufacturing facility in Bulgaria that meets Good Manufacturing Process (GMP) standards. This facility will be part of their portfolio for nutraceutical products and licensed immunotherapy treatments3. Once the SAGA OTC listing is in place, Enzolytics plans to issue dividends of SAGA shares and complete funding needed for clinical trials to bring ITV-1 to market3.
News 
Market Data 
Discover 
